A Study of Ruxolitinib and Duvelisib in People With Lymphoma

This study tests a combination of two targeted drugs — ruxolitinib (a JAK inhibitor) and duvelisib (a PI3K inhibitor) — in people with T-cell lymphomas or other rare T-cell or NK-cell blood cancers that have come back or stopped responding to previous treatments. **You may be eligible if...** - You have a confirmed diagnosis of a T-cell lymphoma (such as cutaneous T-cell lymphoma/CTCL, anaplastic large cell lymphoma, T-cell prolymphocytic leukemia, or related conditions) - Your cancer has relapsed or not responded to prior treatment - For some histologies (like CTCL), you need to have tried at least 2 prior therapies - For T-cell prolymphocytic leukemia, no prior treatment is required **You may NOT be eligible if...** - You do not have a confirmed qualifying T-cell or NK-cell lymphoma diagnosis - You have not tried the required prior treatments (for most subtypes) - Your general health or organ function is too poor Talk to your doctor to see if this trial is right for you.